
|Videos|March 16, 2022
Urology Times 50 Innovations Series: BCG therapy for bladder cancer
Author(s)Urology Times staff
"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.
Advertisement
As part of the Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the many ways in which BCG has improved the management of patients with bladder cancer. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
5



















































